Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q2 2023 · 10-Q
Revenue$44.00K$44.00K+780.0% vs Q2 2022 Net Income-$1.56M-$1.56MN/M vs Q2 2022 EPS Diluted-$0.03-$0.03N/M vs Q2 2022 Gross Profit$11,000+175.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Operating Cash Flowderived-$438,000N/M Free Cash Flowderived-$438,000N/M Margins · derivedGross margin25.0%−55.0 pt vs Q2 2022
Operating margin-3420.5%+10919.5 pt vs Q2 2022
Net margin-3538.6%+14981.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end